Pfizer shares gain 9% after Q3FY26 profit up 11%, revenue grows 20%

Pfizer India shares surged 9.33% to Rs 5,209 in Tuesday’s session after the company reported strong Q3FY26 results, with net profit rising 11% and revenue growing 20% year-on-year.

Net profit for the quarter increased 11.1% YoY to Rs 141.8 crore, compared with Rs 127.6 crore a year earlier. Revenue from operations climbed 19.9% YoY to Rs 645 crore, up from Rs 538 crore in Q3FY25, underscoring robust top-line momentum.

The quarter also included exceptional items of Rs 58.20 crore for both the quarter and the nine months ended December 31, 2025.


Strategic partnership with Cipla: Pfizer entered an exclusive Supply and Marketing Agreement with Cipla Limited for four brands—Corex Dx, Corex LS, Dolonex, and Neksium. As part of this arrangement, the company recorded a charge of ~Rs 39.58 crore related to personnel separation costs for field staff, marketing teams, and support functions.

Impact of new labor laws: Following the consolidation of labor laws into four New Labour Codes effective November 21, 2025, Pfizer’s assessment (based on legal guidance) increased ~Rs 18.62 crore in employee benefit provisions, mainly due to revised wage definitions.

Stock performance: Over the past year, Pfizer’s stock has rallied 21%, reflecting strong investor sentiment. The company is currently trading at a market capitalization of Rs 23,833 crore, with a 52-week high of Rs 5,993 and a 52-week low of Rs 3,701.

On the valuation front, Pfizer’s Price-to-Earnings (P/E) ratio stands at 25.53, indicating that investors are paying Rs 25.53 for every Rs 1 of the company’s earnings. Its Price-to-Sales (P/S) ratio is 1.9, meaning the stock trades at 1.9 times its annual revenue, while the Price-to-Book (P/B) ratio of 24.19 reflects that the market values the company significantly above its book value.

In terms of institutional ownership, during the December 2025 quarter, Foreign Portfolio Investors (FPIs) increased their stake slightly from 158 to 162, showing continued interest in the stock. On the other hand, Mutual Funds reduced their holdings marginally from 11.74% to 11.71%, indicating a small pullback by domestic institutional investors. Overall, the trend suggests steady foreign confidence with only minimal adjustments from mutual funds.

From a technical perspective, the 14-day Relative Strength Index (RSI) stands at 51.7, which is considered neutral — neither overbought (above 70) nor oversold (below 30). This implies the stock is trading in a balanced zone without extreme buying or selling pressure. Supporting this, Pfizer shows a strong bullish signal on moving averages, as it is trading above all 8 Simple Moving Averages (SMAs), reflecting consistent strength across short- and long-term trends.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)